Back to homepage

Women’s health

Menopause hormone therapy: latest developments and clinical practice

Authors: Tomas Fait MD, PhD

Menopause hormone therapy still remains a dominant
therapeutic modality in climacteric medicine. The core medical
skill is the ability to choose the optimal MHT preparation for
the given patient. Such choice is based on an understanding of
various clinical and metabolic effects of MHT depending on the
composition, dosage, and the method of application, this article discusses those choices.

More

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Authors: Marisa C Liu MD, MPH, Krishnansu S Tewari MD

This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

More

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Authors: Mariane Teodoro Fernandes MD, Jacob J Adashek BA, Carmelia Maria Noia Barreto MD, Ana Cláudia Barbin Spinosa MD, Barbara de Souza Gutierres MSc, Gilberto Lopes MD, MBA, FAMS, Auro del Giglio MD, PhD, Pedro Nazareth Aguiar Jr MD, MSc

A novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In this review, all available data is summarized, unanswered questions are highlighted, and pharmacological differences between each CDK4/6 inhibitor are discussed.

More

Advances in the use of PARP inhibitor therapy for breast cancer

Authors: Kelly E McCann MD, PhD, Sara A Hurvitz MD

In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.

More

Metformin in the management of diabetes during pregnancy and lactation

Authors: Gagan Priya MD, DM, Sanjay Kalra MD, DM

This review explores the current place of metformin in the management of gestational diabetes and type 2 diabetes during pregnancy and lactation.

More